MT Newswires
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
➖
AI Sentiment
Neutral
5/10
- Home
- BDRX
as of 12-09-2025 4:00pm EST
$4.05
$4.28
-51.38%
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Chart Type:
Time Range:
| Founded: | 2000 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 771.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -53.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.58 - $92.00 | Next Earning Date: | 09-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BDRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.79%
76.79%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Biodexa Pharmaceuticals plc News
BDRX Breaking Stock News: Dive into BDRX Ticker-Specific Updates for Smart Investing
MT Newswires
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
📊
AI Sentiment
Positive
6/10
Compare BDRX vs Leading Stocks
See how BDRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BDRX Biodexa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.